Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions.

SPRINT MIND Investigators for the SPRINT Research Group, Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Doshi J, Erus G, Fine LJ, Gaussoin SA, Harris D, Johnson KC, Kimmel PL, Kurella Tamura M, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT Jr, Wright CB, Williamson JD, Bryan RN.

JAMA. 2019 Aug 13;322(6):524-534. doi: 10.1001/jama.2019.10551.

PMID:
31408137
2.

Who Is Exposed to E-Cigarette Advertising and Where? Differences between Adolescents, Young Adults and Older Adults.

Wagoner KG, Reboussin DM, King JL, Orlan E, Cornacchione Ross J, Sutfin EL.

Int J Environ Res Public Health. 2019 Jul 16;16(14). pii: E2533. doi: 10.3390/ijerph16142533.

3.

Analysis of Long-term Benefits of Intensive Blood Pressure Control-Reply.

Reboussin DM, Pajewski NM, Williamson JD.

JAMA. 2019 Jul 9;322(2):170. doi: 10.1001/jama.2019.5860. No abstract available.

PMID:
31287519
4.

Joint modeling of systolic blood pressure and the primary outcome in Systolic Blood Pressure Intervention Trial.

Reboussin DM, Whelton PK.

J Hypertens. 2019 Aug;37(8):1729. doi: 10.1097/HJH.0000000000002179. No abstract available.

PMID:
31246770
5.

Evidence Supporting the Blood Pressure Treatment Goal of Less Than 130/80 mm Hg.

Reboussin DM, Carey RM, Whelton PK.

Hypertension. 2019 May;73(5):972-974. doi: 10.1161/HYPERTENSIONAHA.119.12804. No abstract available.

PMID:
30879361
6.

Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.

SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Erus G, Fine LJ, Gaussoin SA, Harris D, Hsieh MK, Johnson KC, Kimmel PL, Tamura MK, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nasrallah IM, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT Jr, Wright CB.

JAMA. 2019 Feb 12;321(6):553-561. doi: 10.1001/jama.2018.21442.

7.

Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR 3rd, Polonsky T, Thompson-Paul AM, Vupputuri S.

Circulation. 2018 Oct 23;138(17):e595-e616. doi: 10.1161/CIR.0000000000000601.

PMID:
30354656
8.

Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Riessen E, Shapiro B, Stergiou GS, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V.

J Clin Hypertens (Greenwich). 2018 Nov;20(11):1644-1645. doi: 10.1111/jch.13395. Epub 2018 Oct 17. No abstract available.

9.

Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).

Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, Beddhu S, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT Jr; SPRINT Research Group.

Hypertension. 2018 May;71(5):848-857. doi: 10.1161/HYPERTENSIONAHA.117.10479. Epub 2018 Mar 12.

10.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM; SPRINT Research Group.

Am J Kidney Dis. 2018 Mar;71(3):352-361. doi: 10.1053/j.ajkd.2017.08.021. Epub 2017 Nov 20.

11.

Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR 3rd, Polonsky T, Thompson-Paul AM, Vupputuri S.

J Am Coll Cardiol. 2018 May 15;71(19):2176-2198. doi: 10.1016/j.jacc.2017.11.004. Epub 2017 Nov 13. Erratum in: J Am Coll Cardiol. 2018 May 15;71(19):2272-2273.

12.

Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR 3rd, Polonsky T, Thompson-Paul AM, Vupputuri S.

Hypertension. 2018 Jun;71(6):e116-e135. doi: 10.1161/HYP.0000000000000067. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e145.

PMID:
29133355
13.

Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.

Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V; SPRINT Research Group.

Diabetes Care. 2017 Aug 9. pii: dc170885. doi: 10.2337/dc17-0885. [Epub ahead of print]

14.

Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Raj D, Riessen E, Shapiro B, Stergiou GS, Townsend RR, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V; SPRINT Research Group*.

Hypertension. 2017 Oct;70(4):751-758. doi: 10.1161/HYPERTENSIONAHA.117.09788. Epub 2017 Jul 31.

15.

Effects of Intensive BP Control in CKD.

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J; SPRINT Research Group.

J Am Soc Nephrol. 2017 Sep;28(9):2812-2823. doi: 10.1681/ASN.2017020148. Epub 2017 Jun 22.

16.

Effects of a lifestyle intervention on REM sleep-related OSA severity in obese individuals with type 2 diabetes.

Shechter A, Foster GD, Lang W, Reboussin DM, St-Onge MP, Zammit G, Newman AB, Millman RP, Wadden TA, Jakicic JM, Strotmeyer ES, Wing RR, Pi-Sunyer FX, Kuna ST; Sleep Ahead Research Group of the Look Ahead Research Group.

J Sleep Res. 2017 Dec;26(6):747-755. doi: 10.1111/jsr.12559. Epub 2017 May 31.

17.

Comparing the SPRINT and the HOPE-3 Blood Pressure Trial.

Whelton PK, Reboussin DM, Fine LJ.

JAMA Cardiol. 2016 Nov 1;1(8):855-856. doi: 10.1001/jamacardio.2016.2051. No abstract available.

PMID:
27604076
18.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Wright JT Jr, Whelton PK, Reboussin DM.

N Engl J Med. 2016 Jun 9;374(23):2294. doi: 10.1056/NEJMc1602668. No abstract available.

PMID:
27276569
19.

SPRINT Trial Results: Latest News in Hypertension Management.

Cushman WC, Whelton PK, Fine LJ, Wright JT Jr, Reboussin DM, Johnson KC, Oparil S; SPRINT Study Research Group.

Hypertension. 2016 Feb;67(2):263-5. doi: 10.1161/HYPERTENSIONAHA.115.06722. Epub 2015 Nov 9. Review. No abstract available.

20.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT.

N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506.

21.

The Effect of Changes in Cardiorespiratory Fitness and Weight on Obstructive Sleep Apnea Severity in Overweight Adults with Type 2 Diabetes.

Kline CE, Reboussin DM, Foster GD, Rice TB, Strotmeyer ES, Jakicic JM, Millman RP, Pi-Sunyer FX, Newman AB, Wadden TA, Zammit G, Kuna ST; Sleep AHEAD Research Group of the Look AHEAD Research Group.

Sleep. 2016 Feb 1;39(2):317-25. doi: 10.5665/sleep.5436.

22.

Sleep architecture following a weight loss intervention in overweight and obese patients with obstructive sleep apnea and type 2 diabetes: relationship to apnea-hypopnea index.

Shechter A, St-Onge MP, Kuna ST, Zammit G, RoyChoudhury A, Newman AB, Millman RP, Reboussin DM, Wadden TA, Jakicic JM, Pi-Sunyer FX, Wing RR, Foster GD; Sleep AHEAD Research Group of the Look AHEAD Research Group.

J Clin Sleep Med. 2014 Nov 15;10(11):1205-11. doi: 10.5664/jcsm.4202.

23.

Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.

Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, Kaysen GA, Kimmel PL, Raj DS, Ricardo AC, Wright JT Jr, Sedor JR, Rocco MV, Freedman BI; Systolic Blood Pressure Intervention Trial (SPRINT).

Kidney Int. 2015 Jan;87(1):169-75. doi: 10.1038/ki.2014.254. Epub 2014 Jul 16.

24.

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK; SPRINT Study Research Group.

Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5. Erratum in: Clin Trials. 2017 Apr;14(2):222.

25.

Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes.

Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP, Zammit G, Newman AB, Wadden TA, Jakicic JM, Wing RR, Pi-Sunyer FX, Foster GD; Sleep AHEAD Research Group of the Look AHEAD Research Group.

Sleep. 2013 May 1;36(5):641-649A. doi: 10.5665/sleep.2618.

26.

Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study.

Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, Kitabchi AE, Faulconbridge LF, Kitzman DW, Espeland MA; Look AHEAD Research Group.

Obesity (Silver Spring). 2012 Oct;20(10):2048-56. doi: 10.1038/oby.2012.33. Epub 2012 Feb 13.

27.

Associations of sleep disturbance and duration with metabolic risk factors in obese persons with type 2 diabetes: data from the Sleep AHEAD Study.

St-Onge MP, Zammit G, Reboussin DM, Kuna ST, Sanders MH, Millman R, Newman AB, Wadden TA, Wing RR, Pi-Sunyer FX, Foster GD; Sleep AHEAD Research Group.

Nat Sci Sleep. 2012 Dec 3;4:143-50. doi: 10.2147/NSS.S35797. Print 2012.

28.

A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study.

Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, Tracy RP, Pi-Sunyer FX, Ballantyne CM; Look AHEAD Research Group.

Diabetes Care. 2010 Nov;33(11):2297-303. doi: 10.2337/dc10-0728. Epub 2010 Aug 3.

29.

HLA genotyping in the international Type 1 Diabetes Genetics Consortium.

Mychaleckyj JC, Noble JA, Moonsamy PV, Carlson JA, Varney MD, Post J, Helmberg W, Pierce JJ, Bonella P, Fear AL, Lavant E, Louey A, Boyle S, Lane JA, Sali P, Kim S, Rappner R, Williams DT, Perdue LH, Reboussin DM, Tait BD, Akolkar B, Hilner JE, Steffes MW, Erlich HA; T1DGC.

Clin Trials. 2010;7(1 Suppl):S75-87. doi: 10.1177/1740774510373494. Epub 2010 Jul 1.

30.

Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study.

Adams P, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively BM, Vogt T, Sholinsky P, Thomson E, Dawkins FW, Gordeuk VR, Eckfeldt JH.

Can J Gastroenterol. 2009 Nov;23(11):769-72. Review.

31.

Potential nonresponse bias in a clinical examination after initial screening using iron phenotyping and HFE genotyping in the hemochromatosis and iron overload screening study.

Speechley M, Barton JC, Passmore L, Harrison H, Reboussin DM, Harris EL, Rivers CA, Fadojutimi-Akinsiku M, Wenzel L, Diaz S.

Genet Test Mol Biomarkers. 2009 Dec;13(6):721-8. doi: 10.1089/gtmb.2009.0003.

32.

Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study.

Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC, Hoogeveen RC, Pi-Sunyer FX, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Obesity, Inflammation, and Thrombosis Research Group.

Diabetes Care. 2010 Jan;33(1):197-9. doi: 10.2337/dc09-1235. Epub 2009 Oct 19.

33.

Relationships of serum free thyroxine and erythrocyte measures in euthyroid HFE C282Y homozygotes and control subjects: the HEIRS study.

Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH; Hemochromatosis and Iron Overload Screening Study Research Investigators.

Int J Lab Hematol. 2010 Jun;32(3):282-7. doi: 10.1111/j.1751-553X.2009.01182.x. Epub 2009 Aug 25.

PMID:
19706067
34.

Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.

Lamon-Fava S, Asztalos BF, Howard TD, Reboussin DM, Horvath KV, Schaefer EJ, Herrington DM.

Clin Endocrinol (Oxf). 2010 Feb;72(2):169-75. doi: 10.1111/j.1365-2265.2009.03644.x. Epub 2009 May 29.

35.

Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women.

Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath K, Schaefer EJ, Asztalos BF.

Atherosclerosis. 2009 Jul;205(1):325-30. doi: 10.1016/j.atherosclerosis.2008.12.020. Epub 2008 Dec 24.

36.

Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening.

McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH; Hemochromatosis and Iron Overload Screen (HEIRS) Study Research Investigators.

Can J Gastroenterol. 2008 Nov;22(11):923-30.

37.

Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.

Adams PC, Reboussin DM, Barton JC, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, Gordeuk V, Dawkins F, Eckfeldt JH.

Int J Lab Hematol. 2008 Aug;30(4):300-5. doi: 10.1111/j.1751-553X.2007.00956.x.

PMID:
18665827
38.

Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study.

Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH; Hemochromatosis and Iron Overload Screening Study Research Investigators.

Thyroid. 2008 Aug;18(8):831-8. doi: 10.1089/thy.2008.0091.

39.

Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population.

Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, Reiss JA, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt JH, Chen WP, Passmore L, Dawkins FW.

Am J Hematol. 2008 Aug;83(8):618-26. doi: 10.1002/ajh.21179.

40.

Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

McLaren CE, Gordeuk VR, Chen WP, Barton JC, Acton RT, Speechley M, Castro O, Adams PC, Snively BM, Harris EL, Reboussin DM, McLachlan GJ, Bean R; Hemochromatosis and Iron Overload Screening Study Research Investigators.

Transl Res. 2008 Feb;151(2):97-109. doi: 10.1016/j.trsl.2007.10.002. Epub 2007 Nov 9.

41.

Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women.

Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath KV, Cupples LA, White C, Demissie S, Schaefer EJ, Asztalos BF.

Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):575-9. doi: 10.1161/ATVBAHA.107.157123. Epub 2008 Jan 3.

PMID:
18174456
42.

Biological variability of transferrin saturation and unsaturated iron-binding capacity.

Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Gordeuk VR, Lovato L, Eckfeldt JH.

Am J Med. 2007 Nov;120(11):999.e1-7.

43.

HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.

Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, Speechley MR, Reiss JA, Press RD, Dawkins FW; Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators.

Genet Test. 2007 Fall;11(3):269-75.

PMID:
17949288
44.

Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening.

Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, Eckfeldt JH, McLaren CE, Reiss JA, McLaren GD, Reboussin DM, Gordeuk VR, Speechley MR, Press RD, Dawkins FW; Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators.

Am J Hematol. 2008 Feb;83(2):126-32.

45.

Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study.

McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, Acton RT, Harris EL, Ruggiero AM, Castro O; Hemochromatosis and Iron Overload Screening Study Research Investigators.

Am J Hematol. 2007 Oct;82(10):898-905.

46.

Serum ferritin and transferrin saturation in Asians and Pacific Islanders.

Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Leiendecker-Foster C, Holup JL, Passmore LV, Eckfeldt JH, Lin E, Adams PC.

Arch Intern Med. 2007 Apr 9;167(7):722-6.

PMID:
17420432
47.
48.

Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, Press RD, Adams PC, McLaren GD, Dawkins FW, McLaren CE, Reboussin DM.

Blood Cells Mol Dis. 2007 May-Jun;38(3):247-52. Epub 2007 Feb 5.

49.

Mixture models of serum iron measures in population screening for hemochromatosis and iron overload.

McLaren CE, Li KT, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, Eckfeldt JH, Moses GC, Adams PC.

Transl Res. 2006 Oct;148(4):196-206.

PMID:
17002922
50.

Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study.

Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, Bent TC, Vogt TM, Castro O.

Diabetes Care. 2006 Sep;29(9):2084-9.

PMID:
16936157

Supplemental Content

Loading ...
Support Center